Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer to proceed.
特拉華法官駁回了GSK Plc（紐交所：GSK）和其他藥品公司提起上訴的請求，裁定允許超過70,000起聲稱胃灼熱藥物澤替丹引起癌症的訴訟繼續進行。
This ruling, made by Judge Vivian Medinilla of the Delaware Superior Court, means the drugmakers—Pfizer Inc (NYSE:PFE), Sanofi SA (NASDAQ:SNY), and Boehringer Ingelheim—must seek permission directly from the Delaware Supreme Court to appeal. GSK confirmed it has already submitted its appeal.
特拉華高級法院的Vivian Medinilla法官作出的這一裁決意味着製藥公司Pfizer Inc（紐交所：PFE），Sanofi SA（納斯達克：SNY）和Boehringer Ingelheim必須直接向特拉華最高法院申請上訴。 GSK確認它已經提交了上訴。
Also Read: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac.
還讀：輝瑞同意解決1萬多起有關停售胃灼熱藥物澤替丹與癌症風險相關的訴訟。
If the state high court rejects the appeal, the Zantac lawsuits will advance to trial. Jennifer Moore, a lawyer for the plaintiffs, remarked, "Judge Medinilla resoundingly rejected GSK, Boehringer Ingelheim, Pfizer, and Sanofi's attempt to end-run around the jury system in Delaware."
如果州最高法院駁回上訴，澤替丹訴訟將推進至庭審。原告律師Jennifer Moore稱，“Medinilla法官堅定地拒絕了GSK，Boehringer Ingelheim，Pfizer和Sanofi繞過特拉華州陪審團系統的企圖。”
GSK maintained in a statement that "the scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer." Ranitidine is the active ingredient in Zantac, but it has been discontinued.
GSK在一份聲明中表示，“科學共識仍然是，沒有一致或可靠的證據表明雷尼替丁增加了任何癌症的風險。”雷尼替丁是澤替丹的活性成分，但已停產。
Lawsuits began to accumulate after the FDA in 2020 asked manufacturers to withdraw the drug from the market due to concerns that ranitidine could degrade into NDMA, a cancer-causing chemical, over time or when exposed to heat.
在FDA要求製造商從市場上撤回該藥物的2020年之後，訴訟開始積累，原因是擔心雷尼替丁會隨着時間的推移或暴露在熱中分解成致癌化學物質NDMA。
The drugmakers argued that Judge Medinilla should have prevented the plaintiffs from presenting expert testimony that Zantac could cause cancer, as a federal judge did in 2022 for about 50,000 claims in Florida.
這些製藥公司認爲，法官Medinilla應該阻止原告提出澤替丹可能會導致癌症的專家證言，就像聯邦法官在佛羅里達州爲大約50,000起訴訟所做的那樣。
These lawsuits depend on expert testimony to proceed. Industry groups, including the U.S. Chamber of Commerce, supported the drugmakers' appeal, claiming that upholding Medinilla's ruling would lower the standards for evidence in Delaware, potentially turning it into a "hotbed of products liability and mass tort litigation."
這些訴訟取決於專家證言才能繼續進行。包括美國商會在內的行業團體支持製藥公司的上訴，聲稱支持Medinilla的裁決會降低特拉華州的證據標準，有可能將其變成“產品責任和集體訴訟的溫牀”。
Earlier, GSK and other pharmaceutical companies bid to halt over 70,000 lawsuits in Delaware concerning the discontinued heartburn drug Zantac gained support from prominent U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.
此前，GSK和其他藥品公司試圖阻止關於停售胃灼熱藥物澤替丹的70,000多起訴訟，在政府部門和製藥研究製造商協會等知名美國行業團體的支持下獲得了成功。
- Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward.
- 澤替丹造成的心靈灼熱繼續困擾GSK，美國法院的裁決允許澤替丹數千起訴訟繼續進行。
Price Action: GSK shares are down 0.50% at $38.19 during the premarket session at last check Tuesday.
價格走勢：截至週二上午最後一次覈查，GSK股價下跌0.50％至38.19美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本文部分內容使用了Benzinga Neuro的幫助。此內容是通過AI工具部分製作的，並由Benzinga編輯進行了審查和發佈。
Photo via Wikimedia Commons
照片通過Wikimedia Commons
譯文內容由第三人軟體翻譯。